SCHEMBL13437320

SCHEMBL13437320

CCOC(=O)c1nc(-c2ccc(F)cc2)sc1CC(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 5/20 0.58
MAPT P10636 6/20 0.46
KDM4E B2RXH2 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 1/20 0.44
HSP90AA1 P07900 1/20 0.44
CRHBP P24387 1/20 0.44
KMT2A Q03164 1/20 0.44
CRHR2 Q13324 1/20 0.44
GRM6 O15303 1/20 0.44
TP53 P04637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13437332 0.90 TRPM8 (0.56) TRPM8MAPTKDM4EL3MBTL1MEN1
SCHEMBL13437328 0.89 TRPM8 (0.49) TRPM8MAPTKDM4EL3MBTL1MEN1
SCHEMBL13437316 0.88 L3MBTL1 (0.60) TRPM8MAPTKDM4ENPC1RAB9A
SCHEMBL13437323 0.87 TARBP2 (0.51) TRPM8MAPTKDM4ENPC1RAB9A
SCHEMBL13437315 0.87 CDC7 (0.58) TRPM8L3MBTL1CDC7DBF4
SCHEMBL13437321 0.86 TRPM8 (0.61) TRPM8MAPTL3MBTL1MEN1KMT2A
SCHEMBL13437312 0.84 RAB9A (0.56) TRPM8MAPTNPC1RAB9AGABRA2
SCHEMBL4822173 0.83 TRPM8 (0.58) TRPM8MAPTKDM4ENPC1RAB9A
SCHEMBL13437319 0.82 ALDH1A1 (0.46) TRPM8KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL13174732 0.82 CDC7 (0.59) TRPM8MAPTKDM4EL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2030974-B1 THIAZOLE NON-NUCLEOSIDE COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS SHANGHAI INST MATERIA MEDICA (CN) 2016-02-17 EP disclosed
US-8653115-B2 Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2014-02-18 US disclosed
US-8653115-B2 Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2014-02-18 US disclosed
US-20100056569-A1 Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2010-03-04 US disclosed
US-20100056569-A1 Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2010-03-04 US disclosed
EP-2030974-A1 HETEROCYCLIC NON-NUCLEOSIDE COMPOUNDS, THEIR PEPARATION, PHARMACEUTICAL COMPOSITION AND THEIR USE AS ANTIVIRAL AGENTS Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2009-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056569-A1 Heterocyclic Non-Nucleoside Compounds, Their Preparation, Pharmaceutical Composition And Their Use As Antiviral Agents TYMP, PNP, NUDT1 TRPM8 3972/4885MAPT 1932/4885KDM4E 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.